copies mL

Related by string. copies ml * Copies . COPIES . Copie : prospectus supplement copies . PPD copies . accompanying prospectus copies . autographed copies . Autographed copies . autographing copies . pirated copies . bootleg copies / MLD . mld . Ml . mls . MLs . Mls . MLER : mg mL . mg ml . Sierra Mist MLS . ml bottle . pg mL . pg ml . Mercedes Benz ML * log# copies mL . -#.# log# copies mL . RNA copies mL *

Related by context. All words. (Click for frequent words.) 82 copies ml 78 IU mL 76 HCV RNA 72 undetectable viral load 72 HBV DNA 69 viral load 68 serum HCV RNA 68 undetectable HCV RNA 68 HIV RNA 67 plasma HCV RNA 67 HBV DNA levels 67 log# 67 viral loads 66 serum HBV DNA 66 log# copies mL 65 mg QD 65 IU ml 65 log# reduction 65 adefovir 64 virologic failure 64 HBeAg seroconversion 63 lopinavir r 63 sustained virologic response 63 virologic response 63 viral suppression 63 atazanavir ritonavir 63 mcg kg 63 ug dose 62 undetectable virus HCV 62 ng dL 62 lopinavir r arm 62 LPV r 62 rapid virologic response 62 detectable HCV RNA 62 sUA 61 undetectable HBV DNA 61 -#.# log# 61 mg BID 61 mg kg dose 61 CCyR 61 HbA1c levels 61 ABC/3TC 61 peginterferon alfa 2a 61 complete cytogenetic 61 mg dL 60 mcg BID 60 pg mL 60 g dL 60 mg TID 60 #mg BID [001] 60 -#.# log# copies mL 60 Peg IFN 60 p = #.# [004] 59 biochemical relapse 59 #mg QD [002] 59 annualized relapse 59 RNA copies mL 59 cells/mm3 59 ribavirin therapy 59 virologic response EVR 59 lamivudine 59 placebo 59 ACR# response 59 #mg QD [001] 59 abacavir lamivudine 59 REYATAZ r 59 CDAI score 59 p = #.# [002] 59 HCV genotype 1 59 p = 59 Index CDAI score 59 IPSS 58 alanine aminotransferase ALT 58 mg dose 58 TDF FTC 58 CIMZIA TM 58 achieved ACR# 58 seroconverted 58 mg ustekinumab 58 undetectable viral loads 58 #mg BID [003] 58 plus methotrexate 58 mg/m2 dose 58 ng mL 58 peginterferon 58 PEG Interferon alfa 58 mcg mL 58 viremia 58 placebo p 58 LEXIVA r 58 microliter 58 DAS# [002] 58 cells mcL 58 response CCyR 58 median PFS 58 adefovir treated 58 seroconversion 58 Crohn Disease Activity 57 complete cytogenetic response 57 genotype 1b 57 amprenavir 57 peginterferon alfa 2b 57 log# IU mL 57 certolizumab 57 pg ml 57 evaluable subjects 57 mL/min/#.# m 2 57 creatinine clearance 57 timepoint 57 statistically significant p 57 μmol L 57 n = 57 -#.# mg dL [002] 57 PASI scores 57 ALT normalization 57 ribavirin RBV 57 HBeAg positive patients 57 VIRAMUNE 57 mcg Albuferon 57 placebo dexamethasone 57 #mg/day [001] 57 tipranavir ritonavir 57 PREZISTA r 57 experienced virologic failure 57 lamivudine monotherapy 57 oxycodone CR 57 cells uL 57 coinfected 57 cEVR 57 ng ml 57 CD4 cell 57 plus ribavirin 57 mcg albinterferon alfa 2b 57 CD4 + cell 57 μg dose 57 HbA1c 57 chlorambucil 57 mg dl 56 serum phosphorus 56 mg Lucentis 56 P = .# 56 HCV viral 56 Index CDAI 56 CDAI 56 virologic breakthrough 56 mg qd 56 aminotransferase elevations greater 56 baseline HbA1c 56 CR nPR 56 median CD4 56 lopinavir 56 pegylated interferon 56 null responders 56 undetectable viral 56 PegIFN RBV 56 HBeAg negative patients 56 QTcF 56 spontaneous bowel movements 56 achieved sustained virologic 56 evaluable patients 56 evaluable 56 virologic 56 genotypic resistance 56 HBeAg 56 lumbar spine BMD 56 A1C levels 56 mg/m2 56 fosamprenavir 56 CD4 counts 56 alfa 2a 56 mL/min/#.# m2 56 virologic suppression 56 RGT arm 56 alanine aminotransferase 56 PSA nadir 56 sustained virological response 56 tipranavir r 56 Pegasys ® 56 mcg dose 56 8mg/kg 56 NNRTI resistance 56 serum testosterone 55 ng dl 55 Hb A1C 55 mEq L 55 ug kg 55 mucosal healing 55 TMC# r 55 endoscopic remission 55 REYATAZ r arm 55 lopinavir ritonavir 55 mmol l 55 Viread Emtriva Sustiva 55 Pegasys plus Copegus 55 ritonavir boosted 55 infliximab monotherapy 55 plasma uric acid 55 antibody titers 55 achieved sustained virological 55 clodronate 55 fasting plasma glucose FPG 55 mcg QD 55 % CI #.#-#.# [003] 55 #.#mg/dL 55 lispro 55 baseline A1C 55 55 binary restenosis 55 CK # plasma concentrations 55 Psoriasis Area 55 LVEF 55 nucleoside naive 55 APTIVUS r 55 ACR# [002] 55 SVR# 55 Free Survival PFS 55 #mg/kg [002] 55 IIIa inhibitors 55 A1c levels 55 mg subcutaneously 55 administered subcutaneously 55 serum ALT 55 hemoglobin A1c levels 55 μg doses 55 μg mL 55 mg kg 55 progression TTP 55 elevated ALT 55 VELCADE melphalan 55 placebo p = 55 achieved statistical significance 55 CrCl 55 plasma concentrations 55 mg d 55 μg 55 umol L 55 entecavir 55 infliximab 55 PREZISTA ritonavir 55 Median PFS 55 achieved PASI 55 sUA levels 55 #μg [002] 55 undetectable hepatitis C 55 mg tid 54 aspartate aminotransferase 54 free survival PFS 54 mmHg systolic 54 mmHg 54 HCV infected 54 virological response 54 severe neutropenia 54 peg IFN 54 corticosteroid dose 54 mg orally 54 cART 54 ertapenem 54 serum potassium 54 serum urate 54 mg RDEA# 54 virological failure 54 preintervention 54 Sustained virologic response 54 rapid virological response 54 seropositive patients 54 lamivudine refractory patients 54 discontinuations due 54 splenectomized patients 54 MADRS score 54 seroprotection 54 #mg/m# [001] 54 dapagliflozin plus 54 % CI #.#-#.# [007] 54 virological suppression 54 urate lowering therapy 54 Solid Tumors criteria 54 efavirenz EFV 54 lopinavir ritonavir Kaletra 54 Cmax 54 HCV RESPOND 2 54 NPH insulin 54 CRp 54 insulin detemir 54 cytogenetic response 54 mCi m 2 54 nonresponders 54 pmol L 54 placebo fluoxetine 54 amoxicillin clavulanate 54 recurrent genital herpes 54 SELENA SLEDAI score 54 μg kg 54 plus MTX 54 4mg/kg 54 #mg/dl 54 mg/m2/day 54 glycated hemoglobin levels 53 Engerix B 53 FEV1 53 mmol L 53 tolterodine ER 53 Negative Syndrome 53 COMBIVIR 53 EDSS score 53 undergone splenectomy 53 q#h 53 HbA 1c 53 primary efficacy endpoint 53 prior chemotherapy regimens 53 telaprevir dosed 53 pegylated interferon alfa 2b 53 mIU L 53 plus dexamethasone 53 plus OBT 53 seronegative 53 HCV genotype 53 receiving VICTRELIS 53 RECIST criteria 53 degarelix 53 #mg/day [002] 53 treatment naïve genotype 53 OADs 53 Kaplan Meier analysis 53 Pred Forte 53 naïve HCV 53 PREZISTA r arm 53 enfuvirtide 53 #.#/#.# mm Hg [003] 53 Montgomery Asberg Depression 53 lactate dehydrogenase 53 fasting plasma glucose 53 neutrophil counts 53 interferon alfa 2a 53 tapentadol ER 53 tipranavir 53 #ug [001] 53 LEXIVA 53 comparator PI r 53 μg ml 53 piperacillin tazobactam 53 ritonavir boosted atazanavir 53 antiretroviral naive 53 AZT zidovudine Retrovir 53 mcg doses 53 leukopenia 53 prior relapsers 53 g dl 53 HAQ DI 53 nmol L 53 Virologic 53 active comparator 53 comparator arm 53 mIU ml 53 PegIFN 53 EDSS scores 53 cytarabine daunorubicin 53 NRTI 53 3mg/kg 53 mL min 53 viral titer 53 aspartate aminotransferase AST 53 Expanded Disability Status 53 mm Hg 53 BARACLUDE ® 53 creatinine ratio 53 dose cohorts 53 ACR# responses 53 NRTIs 53 achieved undetectable HCV 53 PREZISTA rtv 53 #.#ng/ml 53 titers 53 lymphocyte count 53 achieve sustained virologic 53 CSBMs 53 adalimumab 53 nelfinavir 53 eGFR 53 telbivudine 53 dosing cohorts 53 cells μL 53 % Confidence Interval 53 cobicistat 53 ribavirin 53 nevirapine Viramune 53 Viread Emtriva 53 platelet counts 53 statistical significance p 53 nmol liter 53 mg m 52 x ULN 52 HBeAg positive 52 linezolid 52 Median survival 52 #mg BID [002] 52 postintervention 52 darunavir 52 ug mL 52 mm Hg systolic 52 5-FU/LV 52 REYATAZ ® 52 #mg/m# [002] 52 interquartile range 52 CR CRu 52 darunavir r 52 pCR 52 atazanavir 52 ® emtricitabine 52 abacavir 52 serum creatinine 52 Elitek 52 remission CR 52 % CI #.#-#.# [006] 52 tenofovir emtricitabine 52 low dose cytarabine 52 mcg 52 peg interferon 52 #mg q8h 52 Response Evaluation Criteria 52 mIU mL 52 nadolol 52 stage IIIb IV 52 estimated glomerular filtration 52 elevated transaminases 52 serum phosphorous 52 #.#/#.# mmHg [001] 52 RLAI 52 pegylated interferon alpha 52 adjunctive placebo 52 antiviral activity 52 partial remissions 52 chronic HCV genotype 52 hemoglobin concentrations 52 incontinence episodes 52 CI -#.# 52 HOMA IR 52 unfractionated heparin UFH 52 SBMs 52 IRLS score 52 HCV Genotype 52 q8h 52 BPRS PSS 52 titrated 52 -#.# mg dL [001] 52 patients evaluable 52 quetiapine XR 52 hemoglobin A1c HbA1c 52 randomized #:# 52 PEG Intron 52 HBsAg 52 irbesartan 52 d4T 52 nicardipine 52 CIMZIA TM certolizumab pegol 52 nodular partial response 52 baseline CD4 52 HbA 1c levels 52 fasting triglyceride levels 52 desvenlafaxine succinate 52 secondary endpoint 52 3TC lamivudine Epivir 52 Sustained Virologic Response 52 moderate renal impairment 52 receiving INTRON 52 efavirenz 52 Rapid Virological Response 52 oxycodone IR 52 Score DAS# 52 seropositive 52 receiving prophylactic anticoagulation 52 dalteparin 52 microgram kg 52 serum magnesium 52 pegylated interferon alfa 2a 52 protease inhibitor PI 52 tirofiban 52 NNRTI 52 interferon ribavirin 52 FTC TDF 52 hours postdose 52 HbA1C 52 virologically suppressed 51 mg m² 51 calculated creatinine clearance 51 imatinib 51 REMICADE monotherapy 51 darunavir ritonavir 51 indinavir 51 prespecified 51 ALVESCO 51 DAS# remission 51 noninferiority 51 acute gout flares 51 receiving APTIVUS r 51 serum urate levels 51 primary endpoint 51 mg simvastatin 51 inflammatory lesions 51 vicriviroc 51 neutrophil count 51 Viral load 51 mcg kg REBETOL 51 HAART 51 #ng/ml 51 serum uric acid 51 daunorubicin 51 relapsed MM 51 pyrazinamide 51 IFN α 51 mcL 51 HI titers 51 #mmHg [001] 51 aminotransferase levels 51 nanomolar 51 PEG IFN 51 retinal thickness 51 raltegravir 51 hypophosphatemia 51 null responder HCV 51 Peginterferon Alfa 2a 51 anemia hemoglobin 51 mg kg belimumab 51 microg 51 Median progression 51 hemoglobin Hb 51 peginterferon alfa 51 febrile neutropenia 51 YMRS 51 Knodell necroinflammatory score 51 ALND 51 posttreatment 51 Platelet counts 51 mg 51 achieved CCyR 51 treatment naive genotype 51 budesonide pMDI 51 ACR Pedi 51 valacyclovir 51 baseline FEV 51 achieving PASI 51 univariate analysis 51 Solid Tumors RECIST 51 saline placebo 51 CSBM 51 PASI score 51 #mg/dL [002] 51 antiretroviral naïve 51 mL sec 51 Lupuzor ™ 51 ALT flares 51 Baseline characteristics 51 azathioprine 51 ULORIC 51 clinically meaningful improvement 51 oral antidiabetic medication 51 tamsulosin 51 dose cohort 51 peginterferon alfa 2a #KD 51 pegylated interferon alfa 51 Scale PANSS 51 low dose Iluvien 51 definite stent thrombosis 51 hsCRP levels 51 non inferiority 51 randomized 51 baseline LDH 51 HBeAg negative 51 noncarriers 51 plus prednisone prednisolone 51 Pharmacokinetics PK 51 confidence interval CI 51 IFN alfa 51 virologic failures 51 viral kinetics 51 glycosylated hemoglobin HbA1c 51 sd = 51 rizatriptan 51 postop 51 TPV r 51 % CI #.#-#.# [002] 51 Lucentis monotherapy 51 Kaplan Meier estimate 51 transaminases 51 octreotide LAR 51 e antigen HBeAg 51 glimepiride 51 pegIFN 51 PROCTOCORT ® Suppository Hydrocortisone 51 RECIST Response Evaluation Criteria 51 p = .# [002] 51 mg BID dose 51 hepatitis C genotype 51 receiving golimumab 51 XIENCE V PROMUS Stent 51 unfractionated heparin 51 aged ≥ 51 prospectively defined 51 postoperatively 51 pegylated interferon peg IFN 51 ritonavir boosted lopinavir 50 serum aminotransferase levels 50 serum phosphate 50 protease inhibitor mutations 50 fasting blood glucose 50 CI #.#-#.# [001] 50 steroid dexamethasone 50 mm Hg diastolic 50 quetiapine 50 BENICAR HCT 50 titrated glipizide 50 COPEGUS 50 Mg Uk 50 antibody titer 50 serum creatinine levels 50 timepoints 50 FOLFOX4 50 carboplatin paclitaxel 50 Acetate Rectal Suppositories 50 #μg [001] 50 liver histology 50 HAM D# scores 50 plus prednisone 50 mg q#h 50 mL 50 atorvastatin #mg 50 glycated hemoglobin HbA1c 50 mesalamine granules 50 baseline neutrophil counts 50 ug ml 50 Left Ventricular Ejection Fraction 50 MADRS 50 aminotransferase ALT 50 systemic embolism 50 β blocker 50 sitagliptin 50 TMC# [001] 50 mg eq 50 PSADT 50 Aptivus ® 50 glomerular filtration rate 50 tPSA 50 plus GP IIb 50 p = #.# [003] 50 concomitant antibiotics 50 Rating Scale MADRS 50 fluticasone salmeterol 50 mg kg Hematide 50 paricalcitol 50 crossclamp 50 Rapid Virologic Response 50 FluCAM 50 R# #mg BID 50 Pharmacokinetic parameters 50 FOLPI 50 mg subcutaneous 50 ULN 50 per milliliter 50 specific antigen PSA 50 weekly subcutaneous injections 50 rifapentine 50 dexamethasone Decadron 50 dasatinib 50 confirmed CCyR 50 platelet reactivity 50 COPD exacerbation 50 normal ULN 50 Secondary endpoints 50 plasma viremia 50 dose dexamethasone 50 decitabine 50 boosted atazanavir 50 intraocular inflammation 50 mmol L. 50 urine albumin 50 aminotransferases 50 mRCC 50 plasma glucose 50 ALT elevation 50 CsA 50 docetaxel 50 hypokalemia 50 CK MB 50 ISENTRESS 50 treatment naļve 50 statin monotherapy 50 #mg dose [003] 50 K#N 50 Hepsera 50 cGy 50 OGTT 50 NRTI sparing 50 mmHg diastolic 50 intravenous bolus 50 #mg dose [002] 50 p = NS 50 interferon alfa 50 LAB GHRH 50 FOLFOX 50 secondary efficacy endpoint 50 Primary endpoints 50 fasting insulin 50 achieved mucosal healing 50 NRTI backbone 50 iPTH 50 transcriptase inhibitor NNRTI 50 mg doses 50 #mmHg [002] 50 postvaccination 50 rilpivirine 50 HCV SPRINT 50 achieve sustained virological 50 Secondary endpoints included 50 MBq 50 highest tertile 50 Scale EDSS 50 peripheral blood mononuclear 50 #mg doses [002] 50 Treatment Naive Patients 50 Kaplan Meier survival 50 ACTEMRA TM 50 elevated serum creatinine 50 gout flares 50 tiotropium 50 Alzheimer Disease Assessment 50 REBETOL 50 PANSS 50 sinus rhythm 50 NovoLog ® Mix 50 Hb A1c 50 antihypertensive medications 50 cytogenetic responses 50 diuretic chlorthalidone 50 ejection fractions 50 oral rivaroxaban 50 baseline Hb 50 ibandronate 50 virologic responses 50 ADAS cog 50 fluticasone 50 nondiabetic patients 50 DMARD 50 A1C 50 triple nucleoside 50 zolmitriptan 50 Hb levels 50 MCyR 50 dose colchicine 50 statistically significant improvement 49 composite endpoint 49 sham injections 49 lactate dehydrogenase LDH 49 posaconazole 49 ACR# ACR# 49 glycosylated hemoglobin 49 Hazard Ratio HR 49 reduce serum phosphate 49 adalimumab Humira 49 refractory NSCLC 49 Montgomery Åsberg Depression 49 hip BMD 49 T2 lesion volume 49 serum concentrations 49 FOLFOX4 alone 49 laboratory abnormalities 49 NATRECOR R 49 BEACOPP 49 mcg kg min 49 virologically 49 esomeprazole 49 #mg ritonavir 49 tumor progression TTP 49 IELT 49 creatinine 49 plus glycoprotein IIb 49 mU L 49 Ishak fibrosis score 49 q#d 49 VFEND 49 #mg ATC 49 postdose 49 monotherapy 49 #mg/dL [001] 49 oral FTY# 49 nucleoside naive patients 49 baseline PASI 49 nilotinib 49 intravenous REOLYSIN 49 dacarbazine 49 mg/# hr 49 standard chemotherapy regimen 49 mg kg hr 49 advanced adenomas 49 oral prednisone 49 MMSE score 49 doxorubicin docetaxel 49 oral allopurinol 49 urinary N telopeptide 49 aldosterone antagonist 49 serum prostate 49 FOLFOX6 49 metformin monotherapy 49 HCV genotypes 49 salmeterol fluticasone propionate 49 posttransplant 49 subcutaneous enoxaparin 49 boosted protease inhibitor 49 candesartan cilexetil 49 imatinib therapy 49 concentration Cmax 49 recurrent atrial fibrillation 49 bortezomib 49 oral diclofenac 49 plasma urate 49 oral vancomycin 49 serum clusterin levels 49 DAS# CRP 49 ml min 49 recurrent VTE 49 ± SD 49 mCi kg 49 mitoxantrone 49 Zometa hazard 49 Epivir 49 imipenem 49 SCIg 49 Unified Parkinson Disease 49 plus gemcitabine 49 LANTUS R 49 IgG antibody 49 QIDS SR 49 glycated hemoglobin 49 -#.# ± [002] 49 ETDRS 49 atheroma volume 49 mcg linaclotide 49 neurologic progression 49 subcutaneous dose 49 morphometric vertebral fractures 49 tolvaptan 49 alpha 2a 49 alteplase 49 leukocyte count 49 NATRECOR ® 49 TRIZIVIR 49 XIENCE V demonstrated 49 NSTE ACS 49 microalbumin test 49 receiving PEGINTRON 49 untreated mice 49 URTI 49 asthma exacerbation 49 mU liter 49 TEAEs 49 secondary efficacy endpoints 49 demonstrated statistically significant 49 micrograms mL 49 severe exacerbations 49 International Prostate Symptom 49 milligrams mg 49 concomitant medications 49 Viread Emtriva SUSTIVA 49 HIV uninfected 49 HAM D# 49 primary endpoints 49 generalized edema 49 continuous intravenous infusion 49 plasma leptin 49 doxorubicin cyclophosphamide 49 bortezomib refractory 49 zidovudine lamivudine 49 methotrexate monotherapy 49 dose cytarabine 49 zidovudine 49 LDL C 49 allopurinol 49 FOLFIRI 49 adefovir dipivoxil 49 Hb 49 nM 49 Non inferiority 49 locoregional disease 49 Tipranavir 49 intramuscularly 49 dose regimens 49 underwent surgical resection 49 serum potassium levels 49 lopinavir ritonavir plus 49 fluconazole 49 patients coinfected 49 Flu Cy 49 rheumatoid factor 49 5mg/kg 49 mm ³ 49 blood Phe levels 49 Secondary endpoints include 49 CIN3 49 ritonavir 49 glyburide 49 μg liter 49 mg FV 49 doxazosin 49 infliximab therapy 48 ritonavir Norvir 48 3TC 48 NMIBC 48 Durezol 48 etanercept 48 serum phosphorus levels 48 zonisamide SR 48 BENICAR 48 solifenacin 48 Kaplan Meier estimates 48 dexamethasone 48 ARB telmisartan 48 TAXUS Express Stent 48 hematologic toxicity 48 GERD symptom 48 Mg Usa 48 nmol l 48 Target Lesion Revascularization TLR 48 ziprasidone 48 DAPT 48 tapentadol IR 48 anthracycline taxane 48 placebo PBO 48 noninferior 48 uM 48 CD4 count 48 tenofovir FTC 48 Folfox 48 HPV-#/# 48 Brief Psychiatric 48 Q2W 48 creatinine levels 48 CNS LS 48 flutamide 48 Lamictal XR 48 apremilast 48 systolic dysfunction 48 proteinuria 48 serum IGF 48 HAART regimen 48 hypoglycemic events 48 Apidra ® 48 Scale EDSS score 48 mRS 48 recurrent glioblastoma multiforme 48 inhibitory concentration 48 suppressive therapy 48 HCV replicon 48 CD4 cells 48 baseline CD4 + 48 mild renal insufficiency 48 pegylated interferon alpha 2a 48 CIMZIA ™ 48 SCr 48 UPDRS 48 transaminase elevations 48 relapsers 48 paraprotein 48 daily Infergen 48 antiretroviral regimen 48 ADHD RS 48 secondary endpoints 48 highly emetogenic 48 MAS XR 48 leuprorelin 48 XELOX 48 ALT elevations 48 DLTs 48 statistically significant p = 48 statistically significant 48 ddI 48 mycophenolate mofetil 48 certolizumab pegol 48 3mg 48 CANCIDAS 48 dosing frequency 48 cervical intraepithelial neoplasia 48 IV bolus 48 reinfarction 48 PEGASYS ® 48 peginterferon alfa 2a Pegasys 48 ezetimibe simvastatin 48 apnea hypopnea index 48 thyroglobulin 48 Copegus 48 adenoma recurrence 48 tenofovir Viread 48 oblimersen 48 reactogenicity 48 lymphocytosis 48 FluCAM arm 48 bosentan 48 serum CRP 48 X ULN 48 anti HBs 48 rimonabant #mg 48 SELENA SLEDAI

Back to home page